Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.69 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.69 |
| ▸ | MAPT | P10636 | 5/20 | 0.69 |
| ▸ | GAA | P10253 | 5/20 | 0.69 |
| ▸ | MAOA | P21397 | 7/20 | 0.65 |
| ▸ | MAOB | P27338 | 5/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.63 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.63 |
| ▸ | LMNA | P02545 | 4/20 | 0.60 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.60 |
| ▸ | MGAM | O43451 | 1/20 | 0.60 |
| ▸ | TP53 | P04637 | 1/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.60 |
| ▸ | SI | P14410 | 1/20 | 0.60 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.60 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.60 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.57 |
| ▸ | GFER | P55789 | 1/20 | 0.57 |
| ▸ | HPGD | P15428 | 3/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31454902 | 0.85 | MAOB (0.67) | ALDH1A1KDM4EMAPTGAAMAOA | |
| SCHEMBL25393840 | 0.85 | MAOB (0.69) | ALDH1A1KDM4EMAPTGAAMAOA | |
| SCHEMBL29276289 | 0.83 | MAOB (0.63) | ALDH1A1KDM4EMAPTGAAMAOA | |
| SCHEMBL4383562 | 0.82 | MAOB (0.67) | ALDH1A1KDM4EMAPTGAAMAOA | |
| SCHEMBL29749855 | 0.82 | MAOB (0.67) | ALDH1A1KDM4EMAPTGAAMAOA | |
| SCHEMBL27860821 | 0.82 | MAOB (0.69) | ALDH1A1KDM4EMAPTGAAMAOA | |
| SCHEMBL27860820 | 0.82 | MCL1 (0.58) | ALDH1A1KDM4EMAPTGAAMAOA | |
| SCHEMBL661754 | 0.79 | MAOA (0.64) | ALDH1A1KDM4EMAPTGAAMAOA | |
| SCHEMBL31262908 | 0.79 | MAOA (0.63) | ALDH1A1KDM4EMAPTGAAMAOA | |
| SCHEMBL11701538 | 0.78 | MAOB (0.60) | ALDH1A1KDM4EMAPTGAAMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024162299-A1 | FURANOCOUMARIN DERIVATIVE AND USE THEREOF | 静岡県公立大学法人 | 2024-08-08 | — | — | WO | disclosed |
| WO-2023167310-A1 | NOVEL FURANOCOUMARIN DERIVATIVE AND USE THEREOF | 国立研究開発法人理化学研究所 | 2023-09-07 | — | — | WO | disclosed |
| WO-2023167310-A1 | NOVEL FURANOCOUMARIN DERIVATIVE AND USE THEREOF | 国立研究開発法人理化学研究所 | 2023-09-07 | — | — | WO | disclosed |
| US-20120046238-A1 | COUMARIN COMPOUNDS AND THEIR USE FOR TREATING VIRAL INFECTION | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2012-02-23 | — | — | US | disclosed |
| US-20120046238-A1 | COUMARIN COMPOUNDS AND THEIR USE FOR TREATING VIRAL INFECTION | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2012-02-23 | — | — | US | disclosed |
| US-8058427-B2 | Coumarin compounds and their use for treating cancer | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2011-11-15 | — | — | US | disclosed |
| US-8058427-B2 | Coumarin compounds and their use for treating cancer | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2011-11-15 | — | — | US | disclosed |
| US-20090312317-A1 | COUMARIN COMPOUNDS AND THEIR USE FOR TREATING CANCER | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2009-12-17 | — | — | US | disclosed |
| US-20090312317-A1 | COUMARIN COMPOUNDS AND THEIR USE FOR TREATING CANCER | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2009-12-17 | — | — | US | disclosed |
| WO-2009152210-A2 | COUMARIN COMPOUNDS AND THEIR USE FOR TREATING CANCER | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2009-12-17 | — | — | WO | disclosed |
| US-20090312406-A1 | COUMARIN COMPOUNDS AND THEIR USE FOR TREATING VIRAL INFECTION | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2009-12-17 | — | — | US | disclosed |
| US-20090312406-A1 | COUMARIN COMPOUNDS AND THEIR USE FOR TREATING VIRAL INFECTION | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2009-12-17 | — | — | US | disclosed |
| CN-100390261-C | Compositions comprising photo-labile perfume delivery systems | PROCTER & GAMBLE (US) | 2008-05-28 | — | — | CN | disclosed |
| US-7071151-B2 | Compositions comprising photo-labile perfume delivery | PROCTER & GAMBLE COMPANY (US) | 2006-07-04 | — | — | US | disclosed |
| US-20050227879-A1 | Compositions comprising photo-labile perfume delivery | THE PROCTER & GAMBLE COMPANY (US) | 2005-10-13 | — | — | US | disclosed |
| US-20050014663-A1 | Compositions comprising photo-labile perfume delivery | THE PROCTER & GAMBLE COMPANY (US) | 2005-01-20 | — | — | US | disclosed |
| CN-1553948-A | Compositions comprising photo-labile perfume delivery systems | — | 2004-12-08 | — | — | CN | disclosed |
| US-20030125220-A1 | Compositions comprising photo-labile perfume delivery systems | THE PROCTER & GAMBLE COMPANY | 2003-07-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090312406-A1 | COUMARIN COMPOUNDS AND THEIR USE FOR TREATING VIRAL INFECTION | C1R, CYP3A4, CYP3A7 | ALDH1A1 718/4885KDM4E 3612/4885MAPT 3336/4885 |
| US-20120046238-A1 | COUMARIN COMPOUNDS AND THEIR USE FOR TREATING VIRAL INFECTION | C1R, CYP3A4, CYP3A7 | ALDH1A1 718/4885KDM4E 3612/4885MAPT 3336/4885 |
| US-20090312317-A1 | COUMARIN COMPOUNDS AND THEIR USE FOR TREATING CANCER | SIRT3, CBR3, RDX | ALDH1A1 175/4885KDM4E 2566/4885MAPT 4437/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.